Sexual health peptides: a complete guide to PT-141

What sexual health peptides are

The label sexual health peptides covers very different molecules that share one trait: they act on the brain circuits of desire and arousal, not on the blood vessels of genital tissue. The group has three families. The first is the melanocortin analogs, derived from alpha-melanocyte-stimulating hormone (α-MSH): melanotan II, bremelanotide (PT-141) and, outside the sexual field, afamelanotide¹³²³. The second is kisspeptin, the signal that switches on GnRH release in the hypothalamus and, with it, the whole reproductive axis²⁴²⁵. The third is oxytocin, the hypothalamic hormone known for labor and lactation, which has been studied by the nasal route for social and sexual behavior³⁰³².

This guide gathers on one page what human studies show for each, how they compare and where the evidence ends. The library articles that go deeper on each molecule are linked in its section and listed at the end of the page.

How they work: from the hypothalamus, not the vessel

PDE5 inhibitors amplify an erection that has already started, because they act on the smooth muscle of the corpus cavernosum. The peptides in this guide work further upstream. The role of the melanocortin 4 receptor (MC4R) in sexual function was described in 2002: a selective agonist increased erectile activity in normal mice but not in mice lacking the receptor, and copulatory behavior was reduced in mice without it; the receptor was found in spinal cord, hypothalamus, pelvic ganglion and nerve fibers of the glans, but not in rat corpus cavernosum smooth muscle cells².

Bremelanotide is a synthetic α-MSH analog that acts as an agonist at MC3R and MC4R, receptors expressed mainly in the central nervous system; in rats it activated hypothalamic neurons in the same region that connects to the corpus cavernosum³. It activates several melanocortin receptor subtypes, but MC4R is the most relevant at therapeutic doses, and in the brain it is expressed mainly in the medial preoptic area of the hypothalamus. According to animal studies, its effect on desire would come from activating presynaptic MC4Rs in that region and increasing dopamine release¹. Kisspeptin, by contrast, acts on its own receptor (formerly called GPR54); mutations in it cause hypogonadotropic hypogonadism and absent puberty²⁴, and on functional MRI kisspeptin increased limbic activity in response to sexual and couple-bonding stimuli²⁶.

Bremelanotide (PT-141) in women: what the phase 3 trials show

Bremelanotide is the only molecule in the group that went through full clinical development. The two phase 3 RECONNECT trials were identical, randomized, double-blind, placebo-controlled 24-week studies in premenopausal women with hypoactive sexual desire disorder (HSDD). Of 1,267 randomized women, those treated showed a 0.35-point increase in desire and a −0.33 reduction in related distress versus placebo in the integrated analysis (both P < 0.001); nausea, flushing and headache occurred in at least 10% in both studies⁷. The trials were funded by the companies developing the drug⁷. The definitions of a clinically important response used in RECONNECT came from a phase 2b dose-finding trial in the same program¹⁰.

The FDA approved bremelanotide (Vyleesi) in 2019 for premenopausal women with acquired, generalized HSDD not due to another condition, relationship problems or another drug⁸⁹. The label is explicit about its limits: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men," nor to enhance sexual performance⁸.

The debate is about effect size. An independent 2024 analysis noted that results for 8 of the 11 efficacy outcomes registered on clinicaltrials.gov had not been published; when analyzed, effect sizes ranged "from nil to small," and the authors questioned the validity of the scales used in women with HSDD¹¹. Context helps: a meta-analysis of eight randomized trials of drugs for female sexual dysfunction, including bremelanotide, flibanserin and intranasal oxytocin, estimated that 67.7% of the treatment effect was accounted for by placebo¹². The full story of PT-141 and its tanning cousin is in Melanotan II and PT-141: chemical cousins, opposite stories.

PT-141 in men: erectile dysfunction and sildenafil non-responders

Before turning to women, PT-141 was studied in men. Intranasally, in healthy men and in sildenafil-responsive patients with mild to moderate erectile dysfunction, the RigiScan-measured erectile response was significant versus placebo, with the first erection at about 30 minutes and a half-life of 1.85 to 2.09 hours; flushing and nausea were the most common adverse events¹³. Subcutaneously, it produced significant erections in patients with an inadequate response to sildenafil, in a placebo-controlled crossover design¹⁴. Combined with a low dose of sildenafil, the response was greater than with sildenafil alone, with no new adverse events¹⁵.

The largest trial, in 342 men who did not respond to sildenafil, reported positive clinical results in 33.5% with bremelanotide versus 8.5% with placebo (p = 0.03), with more adverse effects in the active group¹⁶. Since 2023, the journal that published it has attached an editorial expression of concern¹⁶. Later development continued with an on-demand subcutaneous form for women with HSDD⁹. The mechanism, each male trial and their limitations are covered in PT-141 in men: a central, not vascular, mechanism.

Melanotan I and II: from tanning to case reports

Melanotan II is the chemical predecessor of PT-141. In a small pilot phase 1 study in healthy volunteers it produced mild nausea, intermittent spontaneous erections for 1 to 5 hours and, in two subjects, increased pigmentation of the face and upper body⁴. In two small double-blind crossover trials, it initiated erections in 8 of 10 men with psychogenic erectile dysfunction⁵ and after 12 of 19 injections versus 1 of 21 placebo doses in men with organic risk factors, with increased desire and severe nausea after 4 of 19 injections⁶. It never completed clinical development. Outside research it spread as a "tanning peptide."

What exists on its safety are case reports. A 2017 review described changes in existing moles, new moles (some dysplastic) and four melanomas arising during or shortly after use, without conclusive evidence of a causal link¹⁸. In a systematic review of 179 patients with eruptive nevi, immunosuppressants, chemotherapy or melanotan accounted for 41% of suspected causes¹⁹. Published cases include eruptive nevi and darkening of moles 24 hours after a single melanotan II injection²⁰, low-flow priapism requiring cavernosal aspiration²¹ and a renal infarction most likely attributed to melanotan II, with prior reports of rhabdomyolysis and renal failure in the literature²². A 2026 review lists it among unapproved peptides that lack an established human safety profile³⁴. The contrast is afamelanotide, another α-MSH analog that did go through randomized, placebo-controlled trials, in erythropoietic protoporphyria²³.

Kisspeptin: fertility, desire and functional MRI

Kisspeptin probably has the best human science in the group, almost all from a single London research group. A single injection of kisspeptin-54 triggered egg maturation in 53 women undergoing IVF, with a 23% clinical pregnancy rate²⁵. For sexual function, in 29 healthy men it enhanced limbic activity in response to sexual and bonding stimuli²⁶. In 32 women with HSDD, a 75-minute intravenous infusion modulated brain processing of erotic and attraction stimuli, with no reported adverse effects²⁷. In 32 men with hypoactive sexual desire, the same infusion modulated activity in the brain's sexual-processing network and increased penile tumescence by up to 56% more than placebo²⁸.

Three caveats separate these studies from clinical use. They are single doses in a research center; the primary outcomes are functional MRI changes, not sustained efficacy; and the molecule studied in these patients is kisspeptin-54²⁷²⁸. Kisspeptin-10, the minimal sequence with full intrinsic bioactivity, raised LH as intravenous boluses and testosterone as a continuous infusion in healthy men²⁹. This is developed in Kisspeptin: real science, wrong molecule?.

Intranasal oxytocin and sexual function

Animal studies and some human case reports attribute facilitating effects on sexual behavior to oxytocin³¹. In humans, controlled data do not confirm this. In a 22-week double-blind crossover trial in 30 pre- and postmenopausal women with sexual dysfunction, intranasal oxytocin before intercourse and placebo improved sexual function to the same extent: the FSFI score rose 26% and 31%, with no treatment effect³⁰. In 10 healthy men, intranasal oxytocin raised plasma oxytocin and epinephrine during sexual activity but did not change measures of sexual behavior³¹.

The problem is not unique to sex. A 2016 analysis concluded that intranasal oxytocin studies are generally underpowered and that there is a high probability that most of their published findings do not represent true effects³². In addition, very little of the dose applied to the nose appears to reach cerebrospinal fluid, while blood levels become supraphysiologic³³. The full story, with the large autism and obesity trials, is in Intranasal oxytocin: anatomy of a replication crisis.

How they compare and what risks they carry

• Bremelanotide (PT-141). Phase 3 trials in women, regulatory approval for premenopausal HSDD, modest and debated benefit⁷⁸¹¹. Risks documented in the label: transient blood pressure increase (up to 6 mmHg systolic and 3 mmHg diastolic, peaking at 2–4 hours) and lower heart rate; contraindicated in uncontrolled hypertension or known cardiovascular disease; nausea in 40% (13% needed an antiemetic and 8% discontinued); focal hyperpigmentation in 1% with intermittent use and 38% with daily use for 8 days; may markedly reduce exposure to oral naltrexone⁸.
• Melanotan II. Small pilot trials in men, no full development; risks known only from case reports (nevi, melanoma, priapism, kidney)^56182122.
• Kisspeptin-54. Randomized mechanistic trials, single doses in research centers; well tolerated in those studies²⁷²⁸. For kisspeptin-10 the data are mostly hormonal, in healthy men²⁹.
• Intranasal oxytocin. Negative controlled trial in female sexual function and fundamental critiques of the whole intranasal literature³⁰³²³³.

On ambulatory monitoring in 397 women, systolic increases with bremelanotide versus placebo were 2.4 to 3.2 mmHg and transient, accompanied by lower heart rate¹⁷. For unapproved products, risk also depends on what the vial actually contains: purity, identity and stability. How that is checked is explained in the peptide quality guide: COA, HPLC and purity.

Open questions

• How much real clinical benefit does bremelanotide give? The published outcomes are statistically significant, but a reanalysis of the unpublished ones found them small or nil⁷¹¹.
• Does it work in men? Male data are old and mostly from small trials, and the largest trial is under an expression of concern¹³¹⁴¹⁶.
• Will kisspeptin become a treatment? It still has to move from functional MRI changes after a single infusion to efficacy trials with repeated use²⁷²⁸.
• What is melanotan's real risk? Case reports raise a signal but cannot quantify the risk¹⁸¹⁹.
• How much is placebo? In female sexual dysfunction the placebo response is large, so any study without a control group must be read with great caution¹²³⁰.